Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 19 - Hybrid peptides
Patents for C07K 19 - Hybrid peptides (29,428)
09/2003
09/04/2003US20030166543 Functional antagonists of hedgehog activity
09/04/2003US20030166536 Expression product of DNA encoding human or hybrid human/ mammalian factor VIII, said DNA comprising DNA encoding a modified A2 domain, the DNA having one or more nucleotide substitutions resulting in a coding change at one or more of
09/04/2003US20030166532 Annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation.
09/04/2003US20030166530 Conjugate heat shock protein-binding peptides
09/04/2003US20030166286 Chimeric adenoviral fiber protein and methods of using same
09/04/2003US20030166277 Targeted vaccine delivery systems
09/04/2003US20030166247 Transforming growth factor binding proteins; fusion proteins; knockout animal models; for treatment of osteoporosis/ fractures
09/04/2003US20030166238 Recombinant toxin fragments
09/04/2003US20030166228 Anti-interferon-alpha antibodies
09/04/2003US20030166164 IL-17 like molecules and uses thereof
09/04/2003US20030166163 Immunocytokines with modulated selectivity
09/04/2003US20030166140 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide polyadenylation sequence all
09/04/2003US20030166073 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
09/04/2003US20030166024 Nucleotide sequences coding monoclonal antibody for the prevention, treatment and diagnosis of viral, inflammatory and tumor diseases; gene therapy
09/04/2003US20030165996 Producing protein with altered immunogenicity or improved stability/in situ half-life; veterinary medicine; pharmacology
09/04/2003US20030165873 For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance
09/04/2003US20030165820 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
09/04/2003US20030165519 Administering complex of protein taken from original tumor
09/04/2003US20030165514 Modulate immunology response
09/04/2003US20030165510 Antiinflammatory agents; anticancer agents; cholesterol binding protein
09/04/2003CA2477271A1 Nanostructures containing pilin protein
09/04/2003CA2477270A1 Nanostructures containing antibody assembly units
09/04/2003CA2477249A1 Novel type-1 cytokine receptor glm-r
09/04/2003CA2477171A1 Nanostructures containing pna joining or functional elements
09/04/2003CA2476887A1 Gasp1:a follistatin domain containing protein
09/04/2003CA2476846A1 Method for detection of leptin receptor ligands
09/04/2003CA2476518A1 Compositions and methods for the treatment of immune related diseases
09/04/2003CA2475039A1 Macromolecular conjugates and processes for preparing same
09/03/2003EP1340769A1 CD4-gamma2 and CD4-IgG2 chimeras
09/03/2003EP1340767A2 Polypeptide useful as biomaterial and process for producing the same
09/03/2003EP1340084A2 Proteins, genes and their use for diagnosis and treatment of chronic asthma
09/03/2003EP1339847A2 Transforming growth factor-beta-related molecules and uses thereof
09/03/2003EP1339427A2 Method of producing biospecific molecules by protein trans-splicing
09/03/2003EP0973391A4 Endoderm, cardiac and neural inducing factors
09/03/2003EP0914614B1 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrPsc
09/03/2003EP0607297B1 Hormone analogs with multiple ctp extensions
09/03/2003CN1440459A Expression system
09/03/2003CN1440423A Immunoadhesin for the prevention of rhinovirus infection
09/02/2003US6613882 Use for intracellular transport and membrane presentation of certain epitopes
09/02/2003US6613881 Isolated polypeptide of given amino acid sequence; can use in vaccines
09/02/2003US6613544 Osteoprotegerin
09/02/2003US6613331 Vaccine against Lyme disease
09/02/2003US6613320 Recombinant CD4+ T cells from an individual afflicted with hyper IgM syndrome transformed with vectors carrying either the wild type or the mutagenized CD40Ls, metabolically radiolabeled, and examined for expression
08/2003
08/28/2003WO2003070981A2 Seequences specifically deleted mycobacterium tuberculosis genome and their use in diagnostics and as vaccines
08/28/2003WO2003070765A2 Growth hormone fusion protein
08/28/2003WO2003070752A2 Mhc-peptide complex binding ligands
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003043986A8 Polypeptides of moraxella (branhamella) catarrhalis
08/28/2003WO2003018631A3 Nogo receptor homologues and their use
08/28/2003WO2002101026A3 Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
08/28/2003WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities
08/28/2003WO2002002780A3 Human serine-threonine kinase
08/28/2003WO2001096875A3 Hcv antigen/antibody combination assay
08/28/2003US20030163846 Process for the genetic modification of a plant
08/28/2003US20030162941 Graft polymer of polyester and polypeptide; prevent cyclization
08/28/2003US20030162714 Modulate cell differentiation; muscular disorders; fat metabolism; bone disorders
08/28/2003US20030162696 Modification of peptide; complexing; three-dimensional structure; hydrogen bonding
08/28/2003US20030162173 Nucleic acid modifying enzymes
08/28/2003US20030161837 Crosslinking an immunoglobulin or fragment thereof with anN-hydroxyl-succinimide ester and a maleimide linked vis a polyethyleneoxide spacer and incubating with a polypeptide having a sulfhydryl group (an allergen or autoantigen)
08/28/2003US20030161833 Chlamydia antigens and corresponding DNA fragments and uses thereof
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003CA2477195A1 Deleted sequence in m. tuberculosis, method for detecting mycobacteria using these sequences and vaccines
08/28/2003CA2476854A1 Surrogate antibodies and methods of preparation and use thereof
08/28/2003CA2476764A1 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003CA2476625A1 Mhc-peptide complex binding ligands
08/28/2003CA2420355A1 Novel polypeptide and process for producing the same
08/27/2003EP1338657A1 Sequences specifcally deleted from Mycobacterium tuberculosis genome and their use in diagnosistics and as vaccines
08/27/2003EP1337638A2 Adipocyte complement related protein zacrp13
08/27/2003EP1337636A2 Soluble zcytor 11 cytokine receptors
08/27/2003EP1337634A2 Novel polypeptides involved in immune response
08/27/2003EP1337543A1 Streptavidin-binding peptides and uses thereof
08/27/2003EP1259597A4 Zinc finger domains and methods of identifying same
08/27/2003EP1124577B1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS
08/27/2003EP0750458B1 Terminal complement inhibitor fusion genes and proteins
08/27/2003CN1439022A Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
08/27/2003CN1439021A Parathyroid hormone and parathyroid hormone-related protein receptor modulators
08/27/2003CN1119421C Recombinant fusion proteins to growth hormone and serum albumin
08/26/2003US6610820 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
08/26/2003US6610512 Zinc finger binding domains for GNN
08/26/2003US6610473 Peptides for inhibiting HPV E6-proteins
08/26/2003US6610297 Compositions for treating allergies that include either BSW17 mimotope peptides or antibodies raised against BSW17 mimotope peptides. Also disclosed are methods for the treatment of allergies which involve administration of BSW17 mimeotope
08/21/2003WO2003068934A2 Chimeric molecules for cleavage in a treated host
08/21/2003WO2003068932A2 Method for crystallizing human gsk3 and novel crystal structure thereof
08/21/2003WO2003068822A2 De-immunized (poly)peptide constructs
08/21/2003WO2003068813A2 Group b streptococcus antigen
08/21/2003WO2003068809A2 An herpes simplex virus complex
08/21/2003WO2003068808A1 Novel protein complexes and uses therefor
08/21/2003WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003WO2003068802A2 Materials and methods for preparing dimeric growth factors
08/21/2003WO2003068799A2 Oligomeric molecules and uses thereof
08/21/2003WO2003018052A8 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
08/21/2003WO2002092620A3 Peptides and related molecules that bind to tall-1
08/21/2003WO2002068650A3 Modified and stabilized gdf propeptides and uses thereof
08/21/2003WO2002061102A3 Control of gene expression in plants
08/21/2003WO2002056022A3 Diagnostics, drug screening and treatment for cancer
08/21/2003WO2002035240A3 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
08/21/2003WO2002032925A3 Protein scaffolds for antibody mimics and other binding proteins
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2001085792A3 Mu-1, member of the cytokine receptor family
1 ... 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 ... 295